Patents Assigned to Sugen, Inc.
  • 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20030125370
    Abstract: The present invention relates to certain 5-aralkylsulfonyl-3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that inhibit kinases, in particular met kinase. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.
    Type: Application
    Filed: May 30, 2002
    Publication date: July 3, 2003
    Applicant: SUGEN, INC.
    Inventors: Jingrong Cui, John Ramphal, Congxin Liang, Connie Li Sun, Chung Chen Wei, Peng Cho Tang
  • Nucleic acid molecules encoding CASPR/p190
    Publication number: 20030120051
    Abstract: The 190 kDa Contactin ASsociated PRotein (CASPR/p190) is identified and is implicated as the bridge between contactin and intracellular second messenger systems for the signal caused by the binding of the carboxy anhydrase domain of RPTP&bgr; to contactin and resulting in neurite growth, differentiation or survival. Mammalian CASPR/p190 cDNAs and proteins are described, including those from human and rat. In addition, particular domains of the proteins are characterized.
    Type: Application
    Filed: August 23, 2002
    Publication date: June 26, 2003
    Applicant: SUGEN, INC.
    Inventor: Elior Peles
  • 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors
    Publication number: 20030119819
    Abstract: The present invention relates to certain 3-(4,5,6,7-tetrahydroindol-2-yl-methylidene)-2-indolinone derivatives that inhibit kinases, in particular Src kinase. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.
    Type: Application
    Filed: September 10, 2002
    Publication date: June 26, 2003
    Applicant: Sugen, Inc.
    Inventors: Congxin Liang, Huiping Guan, Peng Cho Tang, Robert A. Blake
  • PYK2 related products and methods
    Publication number: 20030119067
    Abstract: The present invention features a method for treatment of an organism having a disease or condition characterized by an abnormality in a signal transduction pathway, wherein the signal transduction pathway includes a PYK2 protein. The invention also features methods for diagnosing such diseases and for screening for agents that will be useful in treating such diseases. The invention also features purified and/or isolated nucleic acid encoding a PYK2 protein.
    Type: Application
    Filed: November 13, 2002
    Publication date: June 26, 2003
    Applicant: Sugen, Inc.
    Inventors: Sima Lev, Joseph Schlessinger
  • 3-(cycloalkanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
    Patent number: 6579897
    Abstract: The present invention relates to novel 3-(cycloalkano-heteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: December 31, 2001
    Date of Patent: June 17, 2003
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerlad McMahon
  • Indolinone combinatorial libraries and related products and methods for the treatment of disease
    Publication number: 20030108946
    Abstract: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1′ position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety.
    Type: Application
    Filed: February 19, 2002
    Publication date: June 12, 2003
    Applicant: SUGEN, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
  • rdgB proteins and related products and methods
    Patent number: 6576442
    Abstract: The present invention features a method for treatment of an organism having a disease or condition characterized by an abnormality in a signal transduction pathway, wherein the signal transduction pathway includes a rdgB protein. The invention also features methods for diagnosing such diseases and for screening for agents that will be useful in treating such diseases. The invention also features purified and/or isolated nucleic acid encoding a rdgB protein.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: June 10, 2003
    Assignees: Sugen, Inc., New York University Medical Center
    Inventors: Sima Lev, Gregory D. Plowman, Joseph Schlessinger
  • Pyrrole substituted 2-indolinone protein kinase inhibitors
    Publication number: 20030105151
    Abstract: The present invention relates to novel pyrrole substituted 2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: February 25, 2002
    Publication date: June 5, 2003
    Applicant: SUGEN, INC.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Pyrrole substituted 2-indolinone protein kinase inhibitors
    Patent number: 6573293
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: June 3, 2003
    Assignees: Sugen, Inc., Pharmacia & Upjohn Co.
    Inventors: Peng Cho Tang, Todd A. Miller, Xiaoyuan Li, Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Tomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
  • Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
    Publication number: 20030100555
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: April 9, 2002
    Publication date: May 29, 2003
    Applicant: Sugen. Inc.
    Inventors: Connie Li Sun, Chung Chen Wei, Peng Cho Tang, Marcel Koenig, Yong Zhou, Tomas Vojkovsky, Asaad S. Nematalla
  • 2-indolinone derivatives as modulators of protein kinase activity
    Patent number: 6569868
    Abstract: The present invention relates to novel imidazoly 2-indolinones and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: May 27, 2003
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, G. David Harris
  • Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
    Publication number: 20030092079
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of cell proliferative disorders wherein a protein tyrosine kinase or protein tyrosine phosphatase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins is involved. This invention is based, in part, on the surprising discovery that the adaptor protein, GRB-2, binds the intracellular BCR-ABL tyrosine kinase product in vivo and is necessary for the activation of the oncogenic potential of the BCR/ABL product. The present invention further relates to protein tyrosine kinase/adaptor protein complexes and the uses of these complexes for the identification of agents capable of decreasing or inhibiting the interaction between the members of such complexes.
    Type: Application
    Filed: July 12, 2002
    Publication date: May 15, 2003
    Applicant: New York University/Duke University/Sugen Inc.
    Inventors: Joseph Schlessinger, Mikhail L. Gishizky, Ann Marie Pendergast
  • 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors
    Publication number: 20030092917
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Application
    Filed: February 15, 2002
    Publication date: May 15, 2003
    Applicant: SUGEN, INC.
    Inventors: Huiping Guan, Congxin Liang, Li Sun, Peng Cho Tang, Chung Chen Wei, Tomas Vojkovsky, Qingwu Jin, Paul M. Herrinton, Michael A. Mauragis
  • Protein tyrosine phosphatase PTP20 and related products and methods
    Publication number: 20030073120
    Abstract: The present invention relates to a novel polypeptide, PTP20, and to nucleic acid molecules encoding the polypeptide. The invention also relates to nucleic acid molecules encoding portions of the phosphatase, nucleic acid vectors containing PTP20 related nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying compounds that bind PTP20 or abrogate its interactions with natural binding partners. Also disclosed are methods for diagnosing abnormal conditions in an organism with PTP20 related molecules or compounds.
    Type: Application
    Filed: September 16, 2002
    Publication date: April 17, 2003
    Applicant: SUGEN, INC.
    Inventors: Naohita Aoki, Axel Ullrich
  • 3-(Piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
    Publication number: 20030069421
    Abstract: The present invention relates to novel 3-(piperazinyl-benylidenyl)-2-indolinone compounds and derivatives and physiologically acceptable salts thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Application
    Filed: July 24, 2002
    Publication date: April 10, 2003
    Applicant: SUGEN, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Laura Kay Shawver, Klaus Peter Hlrth
  • 4-aryl substituted indolinones
    Publication number: 20030069297
    Abstract: The present invention relates to 4-arylindolinones, as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention also relates to methods for treating protein kinase related disorders.
    Type: Application
    Filed: December 20, 2001
    Publication date: April 10, 2003
    Applicant: Sugen, Inc.
    Inventors: Jingrong Jean Cui, Ruofei Zhang, Hong Shen, Ji Yu Chu, Fang-Jie Zhang, Marcel Koenig, Steven Huy Do, Xiaoyuan Li, Chung Chen Wei, Peng Cho Tang
  • Novel megakaryocytic protein tyrosine kinases
    Publication number: 20030054527
    Abstract: The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryocytes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease.
    Type: Application
    Filed: October 16, 2001
    Publication date: March 20, 2003
    Applicant: SUGEN, INC.
    Inventors: Axel Ullrich, Mikhail Gishizky, Irmingard Sures
  • 3-Methylidenyl-2-indolinone modulators of protein kinase
    Patent number: 6531502
    Abstract: The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: March 11, 2003
    Assignee: Sugen, Inc.
    Inventors: Pen Cho Tang, Li Sun, Todd Anthony Miller, Congxin Liang, Ngoc My Tran, Anh Thi Nguyen, Asaad Nematalla
  • Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
    Patent number: 6528270
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of cell proliferative disorders wherein a protein tyrosine kinase or protein tyrosine phosphatase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins is involved. This invention is based, in part, on the surprising discovery that the adaptor protein, GRB-2, binds the intracellular BCR-ABL tyrosine kinase product in vivo and is necessary for the activation of the oncogenic potential of the BCR/ABL product. The present invention further relates to protein tyrosine kinase/adaptor protein complexes and the uses of these complexes for the identification of agents capable of decreasing or inhibiting the interaction between the members of such complexes.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: March 4, 2003
    Assignees: Sugen, Inc., Duke University, New York University
    Inventors: Joseph Schlessinger, Mikhail L. Gishizky, Ann Marie Pendergast
  • Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
    Patent number: 6525072
    Abstract: The present invention relates to novel geometrically restricted 2-indolinones and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: February 25, 2003
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Todd Anthony Miller, Li Sun, Ngoc My Tran, Asaad Nematalla, Anh Thi Nguyen